Ciloa’s recombinant exosomes permit the antibody development against the most complex membrane antigens.
Current technologies have to face 4 bottlenecks specific of membrane protein targets; all are unlocked by Ciloa’s technology :
- Requirement of a perfect antigen
- Low immunogenicity of membrane antigens
- Time for antibody hit screening against epitopes in a natural context
- Difficulty to characterize all interaction parameters of a lead with its membrane protein target.